Study links Ozempic to higher risk of eye condition that can cause vision loss Elaine Chen By Elaine Chen July 3, 2024

https://www.statnews.com/2024/07/03/ozempic-wegovy-naion-vision-loss-study/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-_T51Bj1Bxt3jXVU0-NWYR12OmOdTgtHI9v6uFJF9paLp7SyNA9saRT6acgd-hkiB3oFogJL2YNQXxQm00b5cNEVdcDkg&_hsmi=314717062&utm_content=314717062&utm_source=hs_email The risks and rewards of GLP-1 weight loss drugs, per two studies The bad news: There’s a potential link between Novo Nordisk’s GLP-1 drugs Ozempic and Wegovy and an eye condition that can cause vision loss, according to an observational study published last week. Researchers analyzed data from a cohort of patients with type 2 diabetes and another including patients with obesity. In both groups, the researchers found that NAION cases occurred most frequently in the first year after the medications were prescribed. STAT’s Elaine Chen has more on the risk. But there’s some good news too: Separate research published last week found that GLP-1 drugs are more effective in mitigating the risk of 10 obesity-associated cancers than the type 2 diabetes drug alternatives. The retrospective study, published Friday in JAMA Network Open, measured results for a cohort of more than 1.6 million patients with type 2 diabetes from 2005 to 2018 who were prescribed GLP-1s, insulin, or metformin. STAT’s Rohan Rajeev has the details on the benefits. GLP-1s associated with lower risk of 10 obesity-related cancers, study shows By Rohan RajeevJuly 5, 2024 https://www.statnews.com/2024/07/05/glp1s-lower-risk-of-10-obesity-associated-cancer-study/?utm_campaign=morning_rounds&utm_medium=email&_hsenc=p2ANqtz-8q4P6V1_tsB6xGMsn6Dtw5YYcTkf4ezj9FgYlvM8e9j138ghFz4XRpfZJ1ooVeRD_LkrC3Es48wCLDRxoKij1hyMazCw&_hsmi=314717062&utm_content=314717062&utm_source=hs_email